ABSTRACT Regional vascular responses to the thromboxane A2 analogue U46619 and effects of the selective thromboxane receptor blocking drug vapiprost on these responses were examined in anesthe tized dogs. Hemodynamic responses to U46619 (0.5 pg/kg into the left atrium), norepinephrine (NE, 0.3,ug/kg, i.v.) and angiotensin II (All, 30 or 60 ng/kg, i.v.) were periodically tested before and after administration of vapiprost (10, 30 or 100 mg/kg, i.v.) or its vehicle. In the absence of vapiprost, U46619 increased total peripheral (TPR), vertebral (VR), coronary (CR) and renal (RR) vascular re sistance by 60.1 ± 4.7%, 33.6 ± 4.9%, 15.3 ± 1.3% and 120.8 ± 17.4%, respectively, indicating that vasoconstrictor responses to U46619 were most prominent in the renal vascular bed as compared to those in the vertebral or coronary vasculatures. Vapiprost as well as the vehicle did not affect the base line hemodynamics. However, vapiprost apparently inhibited the U46619-induced vasoconstriction in all measured vascular beds in a dose-related manner without attenuating vasoconstrictor responses to NE and All, although significantly larger inhibition of U46619-induced increases in RR was observed as compared to the inhibitions of VR and CR. These results demonstrate that there was a regional differ ence both in the vasoconstrictor responses to U46619 and in the blocking effects of vapiprost, and indi cate that vapiprost is a potent and selective antagonist for thromboxane receptors in vivo.
Thromboxane A2 (TXA2) is a potent platelet aggre gatory and vasoconstrictor autacoid, which has been im plicated in various pathophysiological conditions such as myocardial infarction, transient ischemic attacks, Raynaud's disease and lupus nephritis (1, 2) . The bio logical effects of TXA2/prostaglandin endoperoxide are mediated through a specific receptor termed a TP receptor (3), whose molecular structure has recently been reported (4) . Thus, much effort has been ex pended to search for selective antagonists of TP-recep tors in order to prevent the deleterious effects of TXA2, and a few of these drugs are now available for clinical studies (5) . and isolated vascular and airway smooth muscles with out partial agonist activities (2, 6, 7) . Preliminary in vivo studies have also demonstrated that systemically administered vapiprost appears to effectively block both platelet aggregation and vasoconstriction induced by stimulation via TP-receptors in animals (8) and humans (9) . However, hemodynamic effects of this drug and its in vivo TP-receptor blocking actions, especially in terms of the specificity and potency, have not been fully investigated in whole animals. Therefore, the aim of this study was, first, to elucidate the cardiovascular properties of the specific TP-receptor agonist U46619 and, second, to evaluate the acute effect of vapiprost on the systemic hemodynamics and regional hemody namic responses of important organs such as the brain, heart and kidney to the TXA2 mimetic U46619, norepi nephrine (NE) or angiotensin II (All) in anesthetized dogs. For this purpose, aortic, vertebral, coronary and renal arterial blood flows were continuously and simul taneously measured in the same dog by electromagnetic flowmeters along with aortic pressure (10) .
MATERIALS AND METHODS

Experimental setup
Twenty-three mongrel dogs of either sex weighing 10 -18 kg were anesthetized with sodium pentobarbital (25 mg/kg, i.v.), and were ventilated by a Harvard res pirator (model 607). A catheter filled with heparinized saline (0.9% NaCl) was inserted through the left ca rotid artery into the aortic root and connected to a pres sure transducer (Nihon Kohden, TP-200T) for the measurement of aortic pressure (AoP). The left verte bral artery was dissected free just before entering the transverse foramen of the sixth cervical vertebrae. The left renal artery was exposed by a retroperitoneal approach through a flank incision. A left thoracotomy was performed through the fifth intercostal space. The pericardium was opened, and the heart was suspended in a pericardial cradle. The ascending aorta and the proximal portion of the left circumflex coronary artery (LCX) were dissected free from surrounding tissues. Electromagnetic flow probes (Statham, SP7515 and SP7518) of appropriate sizes were placed around the vertebral artery, the renal artery, the LCX and the ascending aorta, and were connected to electromagnetic flowmeters (Statham, SP2204) for the measurement of vertebral (VBF), renal (RBF), coronary (CBF) arterial and aortic blood flow (AoF), respectively. The four flowmeters were synchronized with each other via con nectors to avoid any electromagnetic interaction among the flow probes. A catheter-tip manometer (Millar, PC 350) was introduced through the left atrial appendage into the left ventricular cavity to measure left ventricu lar pressure (LVP). A polyvinyl tube (10 cm long) filled with heparinized saline was inserted through the left atrial appendage into the left atrium for administration of U46619.
Mean blood flow was obtained by using an electronic resistance-capacitance filter with a 5-sec time constant. The first derivative of LVP (LVdP/dt) was derived from differentiating the LVP signal with an electronic differentiator (Nihon Kohden, ED-601G). Heart rate was continuously counted with a cardiotachometer (Nihon Kohden, AT-600G) triggered by the LVP pulse. Data were continuously recorded on an eight-channel pen oscillograph (NEC San-ei, 8K23-L) and simul taneously stored on the magnetic tape of an FM data recorder (Sony, A47).
Experimental protocol
Experiments were started after a stabilization period of at least 30 min. The dogs were divided into four groups. In the first group (n = 8), hemodynamic re sponses to U46619 (0.5 jig/kg into the left atrium), NE (0.3 ,ug/kg, i.v.) and All (30 or 60 ng/kg, i.v.) were re corded in this order as control responses, and then the vehicle for vapiprost (0.3 ml/kg) was given i.v. Re sponses of hemodynamic variables to these three vaso constricting agents were tested at 5, 30, 60, 90 and 120 min after administration of the vehicle. In the second, third and fourth groups, the same experimental pro tocol was performed as in the first group, but vapiprost at doses of 10,ug/kg, i.v. (n = 4), 30,ug/kg, i.v. (n = 4) and 100,ug/kg, i.v. (n = 7) instead of the vehicle were given, respectively.
Drugs
The compounds employed in this study were vapi prost (SN-309, Nippon Glaxo, Ltd., Tokyo), U46619 ((15S)-hydroxy-11 a ,9a-(epoxymethano)prosta-5Z,13E dienoic acid, Funakoshi Co., Ltd., Tokyo), NE (Sankyo Co., Ltd., Tokyo) and All (Peptide Institute, Inc., Osaka). Stock solutions of vapiprost (500 ,ug/ml) were made up of vapiprost (0.05%), ,8-cyclodextrin (0.166%), mannitol (5.0%), NaH2PO4.2H2O (0.093%), Na2HPO4 (0.011%) and distilled water, and the pH of the solution was adjusted with NaOH to pH 6.0. The composition of the vehicle for vapiprost was the same as that of the stock solution of vapiprost with the ex ception of the lack of vapiprost and NaOH. The stock solution was diluted with an appropriate volume of vehicle just before use, and vapiprost or the vehicle was given i.v. in a bolus. U46619 was dissolved in ethanol in advance and diluted with 0.2% sodium carbonate, followed by further dilution with saline to the final con centration (10,ug/ml). U46619 containing the final con centration of 0.1% ethanol was administered into the left atrium in a bolus. The vehicle for U46619 (0.05 ml/kg) had virtually no hemodynamic effect. NE and All were dissolved in saline.
Data analyses
Total peripheral (TPR), vertebral (VR), coronary (CR) and renal (RR) vascular resistances were calcu lated as the quotients of the mean AoP and mean AoF, mean VBF, mean CBF and mean RBF, respectively. TPR, thus, in this study does not involve the resistance of coronary vascular beds. Time sequence data were analyzed by two-way analysis of variance, and unpaired data were analyzed with the t-test. The level for statis tical significance was P < 0.05. All results are express ed as means ± S.E.
RESULTS
Systemic and regional vascular responses to U46619, NE and All Doses of U46619, NE and All employed in this study were selected to cause a similar degree of pressor re sponse. In fact, comparable increases in diastolic aortic pressure induced by U46619 (0.5 ,ug/kg), NE (0.3 Mg/kg) and All (30 or 60 ng/kg) in the vehicle group were observed to be 25.1 ± 3.0 mmHg, 26.0 ± 2.6 mmHg and 19.1 ± 2.5 mmHg, respectively. Responses to these agonists disappeared within 5 min after the in jection in most cases. Regional hemodynamic responses to U46619, NE and All obtained before treatment with vapiprost or vehicle are summarized in Fig. 1 . U46619 caused significant decreases in AoF, VBF and RBF, and a small but significant increase in CBF. Only VBF and RBF significantly decreased with NE, while all four flows significantly decreased with All. Significantly larg er decreases in RBF when compared to the response of AoF were observed with each of these three agonists (Fig. 1) , whereas the U46619-induced change in CBF and All-induced changes in VBF and CBF were signifi cantly less potent than those in AoF. All vascular re sistances calculated from each blood flow and mean AoP significantly increased in response to each agonist ( Fig. 1) , although the pattern of the responsiveness of these flows was different among these three vasocon strictors. U46619 elicited significant increases in TPR, VR, CR and RR by 60.1 ± 4.7%, 33.6 ± 4.9%, 15.3 ± 1.3% and 120.8 ± 17.4% above the respective basal value obtained before treatment. Injections of NE and All also increased TPR by 20.8 ± 2.7% and 48.2 ± 9.0%, VR by 29.5 ± 4.9% and 21.5 ± 3.4%, CR by 14.1 ± 1.4% and 23.3 ± 1.8%, and RR by 44.6 ± 3.8% and 139.1 ± 17.5%, respectively. These results indicate that vasoconstrictor responses to U46619 as well as All or NE were the most prominent in the re nal vascular bed as compared to those in the vertebral or coronary vasculatures.
Effects of vapiprost on hemodynamic variables
The highest dose of vapiprost (100 ,ug/kg, i.v.) in this study as well as the lower doses (10 and 30,ug/kg, i.v.) exerted no effect on the time course of systemic hemodynamics at least until 120 min after the injection of the antagonist when compared to that in dogs receiv ing the vehicle (Fig. 2) . As shown in Table 1 , baseline values for this group were comparable to those for the vehicle group. 
Effects of vapiprost on regional vascular responses to U46619, NE and AII
As shown in Fig. 3 , administration of vehicle did not affect the responses to any of these vasoconstrictors with the exception that a small increase in the U46619 induced pressor response was seen 120 min after the administration (Fig. 3A) , whereas vapiprost (100 Mg/kg, i.v.) significantly inhibited the response to U46619 but not those to NE or All (Fig. 3B ). Further more, Fig. 4 demonstrates that vapiprost at 10, 30 and 100,ug/kg, i.v. apparently inhibited the U46619-induced vasoconstriction in all vascular beds measured in the present experiments in a dose-dependent manner, but the vehicle did not. Vasoconstrictor responses to NE and All during the observation period (120 min) were not significantly reduced by vapiprost or the vehicle ex cept that All-induced increases in RR decreased (P < 0.05) from 162 ± 42% to 94 ± 24% at 120 min after administration of vapiprost (100,ug/kg, i.v.). Durations of the inhibitory effect of vapiprost on the vascular responses to U46619 also appear to be dose related in each of the vasculatures. When percentage inhibitions of U46619-induced increases in each vascular resistance by vapiprost at 100 fig/kg, i.v. were averaged out during the observation period, the increases in TPR, VR, CR and RR were inhibited by 70.8 ± 5.3%, 49.3 ± 9.5%, 49.4 ± 6.0% and 86.9 ± 2.6%, respec tively. Thus, the inhibitory degree in RR by vapiprost at this dose was significantly (P < 0.01) larger than that in VR or CR. 
DISCUSSION
The present experiments demonstrate that there was a regional difference in the vasoconstrictor response to systemically given TXA2 analogue U46619 as well as NE or All in the anesthetized dog, being most promi nent in the renal vascular beds as compared to the ver tebral and coronary ones. It is probable that the in crease in vascular resistance induced by U46619 is mainly due to its vasoconstrictor action rather than vascular obstruction resulting from platelet aggregation, since the effects of repeated injections of U46619, simi lar to the effects of the other two agonists NE and All were short-lived and highly reproducible within an in terval of 25 30 min in the vehicle group as recently re ported by another laboratory (11) . In support of this view, Kadowitz and Hyman (12) have suggested that obstruction of the vascular bed by platelet aggregates would contribute little if anything to the increased vascular resistance in response to U46619 in dogs. U46619 has been previously shown to have essentially the same receptor profile as natural TXA2 (13, 14) . Thus, the present findings suggest that a difference in the population and/or sensitivity of TP-receptors may exist among different vessels, as reported in the case of All receptors (15) . Additionally, the relatively weak effect of U46619 in the vertebral and coronary vascu latures, as compared to other vasculatures, may be re lated to previous observations that U46619 stimulated vascular prostacyclin synthesis in vitro (16, 17) and that U46619 enhanced the release of systemic and coronary prostacyclin in dogs (18, 19) . Furthermore, possible in volvement of endothelium-derived relaxing factor in cerebral (20) and coronary (19) arterial responses to U46619 in vivo has been suggested. Such indirect effects of U46619 in addition to the direct vasoconstric tor effect might operate to a relatively large extent in these vasculatures. A facilitatory action of U46619 on the vasoconstrictor response to renal nerve stimulation has recently been reported (21) , and this may also ex plain, at least partly, the effect of U46619 on the abun dantly innervated renal vasculature. The present in vivo results, however, are inconsistent with those in previous in vitro studies, in which TXA2 analogues had a similar contractile potency in different isolated dog or cat arteries such as basilar, coronary, mesenteric and renal arteries (22, 23) , although there is no comparative study with respect to the regional vascular responsive ness to TXA2 or U46619 in vivo, as far as we know. These additional mechanisms may be related to the dis crepancy between the in vivo and in vitro experimental findings described above.
Results of this investigation clearly demonstrate that vapiprost, at doses causing no direct hemodynamic effect, potently blocks vasoconstrictor responses of ver tebral, coronary and renal vascular beds specifically to the TXA2 analogue U46619 in a dose-dependent man ner in anesthetized dogs. These data further confirm the previous findings showing that vapiprost represents a highly selective and potent TP-receptor antagonism, which is evaluated in platelets and vascular and airway smooth muscles obtained from a range of species in cluding humans (6, 7, 9, 24, 25) . Results that vapiprost even at the highest dose employed in this study virtual ly had no effect on the baseline hemodynamics are also consistent with the previous data that this drug has no partial agonist activity (2, 8) , and suggest that the hemodynamic influence of tonic formation and release of TXA2, if any, is presumably negligible in the anes thetized open-chest dog, in contrast to the case of cyclo oxygenase inhibitors such as indomethacin, which has been found to cause an increase in vascular resistance (26, 27) . Therefore, these characteristics of vapiprost indicate that this drug is not only a pharmacological tool as a TP-receptor blocking agent but also may be useful in the treatment of patients with various car diovascular diseases such as transient ischemic attacks, unstable angina and Raynaud's disease that are consi dered to involve TXA2-induced vasoconstriction (1, 2), although it should be noted that species differences may exist in the responsiveness of platelets and vessels to TXA2 and endoperoxide analogues (28) .
The potency and duration of the TP-receptor block ing activity of vapiprost in the renal vascular bed appeared relatively prominent and long-lasting as com pared to those in the vertebral and coronary ones as shown in Fig. 4 . These present results suggest the pos sibility that blockade of the TP-receptor may exert a ben eficial action, particularly in some renal diseases, since renal vasoconstriction due to intrarenal TXA2 produc tion has been found to participate in cyclosporine nephrotoxicity (29) (30) (31) and lupus nephritis (32, 33) . Additionally, enhanced renal vascular reactivity to the TXA2 analogue U46619 has recently been shown in Goldblatt hypertensive rats (34, 35) and genetically hypertensive rats (36) . Thus, these findings imply that the role of renal TP-receptors in regulation of perfusion of the kidney may be important under pathophysio logical conditions in addition to normal conditions.
